Pro-Dex (PDEX) Competitors

Bioventus (NYSE:BVS) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, community ranking, dividends, analyst recommendations, profitability and media sentiment.

Do analysts recommend BVS or PDEX?

Bioventus presently has a consensus target price of $15.00, indicating a potential upside of 91.82%. Pro-Dex has a consensus target price of $52.00, indicating a potential downside of 14.52%. Given Bioventus' higher probable upside, analysts clearly believe Bioventus is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Pro-Dex	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media favor BVS or PDEX?

In the previous week, Bioventus had 3 more articles in the media than Pro-Dex. MarketBeat recorded 9 mentions for Bioventus and 6 mentions for Pro-Dex. Pro-Dex's average media sentiment score of 1.31 beat Bioventus' score of 1.13 indicating that Pro-Dex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pro-Dex	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community believe in BVS or PDEX?

Pro-Dex received 124 more outperform votes than Bioventus when rated by MarketBeat users. However, 63.27% of users gave Bioventus an outperform vote while only 61.75% of users gave Pro-Dex an outperform vote.

Company	Underperform	Outperform
Bioventus	Outperform Votes 31 63.27%	Underperform Votes 18 36.73%
Pro-Dex	Outperform Votes 155 61.75%	Underperform Votes 96 38.25%

Is BVS or PDEX more profitable?

Pro-Dex has a net margin of 11.06% compared to Bioventus' net margin of -7.11%. Pro-Dex's return on equity of 21.68% beat Bioventus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	-7.11%	15.61%	4.01%
Pro-Dex	11.06%	21.68%	12.40%

Which has more volatility and risk, BVS or PDEX?

Bioventus has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, Pro-Dex has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500.

Which has stronger earnings and valuation, BVS or PDEX?

Pro-Dex has lower revenue, but higher earnings than Bioventus. Bioventus is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$573.28M	1.12	-$156.23M	-$0.51	-15.33
Pro-Dex	$61.00M	3.25	$2.13M	$2.01	30.26

Do insiders and institutionals hold more shares of BVS or PDEX?

62.9% of Bioventus shares are owned by institutional investors. Comparatively, 15.3% of Pro-Dex shares are owned by institutional investors. 32.9% of Bioventus shares are owned by insiders. Comparatively, 47.5% of Pro-Dex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Pro-Dex beats Bioventus on 11 of the 18 factors compared between the two stocks.